A cell is a potentially dangerous thing. In unicellular organisms, cells divide and multiply in a manner that is chiefly determined by the availability of nutritional substrates. In a multicellular organism, each cell has a distinct growth potential that is designed to subsume a role in the function of the whole body. Departure from this path to one of uncontrolled cellular proliferation leads to cancer. For this reason, evolution has endowed cells with an elaborate set of systems that cause errant cells to self-destruct. This process of cell suicide is known as apoptosis or programmed cell death and it plays a crucial role in the growth of both normal and malignant cells. In this review, we describe the mechanisms whereby programmed cell death is induced and executed. In particular, we concentrate on how anti-apoptotic signals generated by cytokines promote cell survival and how these signal transduction pathways may be involved in the pathogenesis of neoplasia. Understanding how these processes contribute to tumorigenesis may suggest new therapeutic options. Leukemia (2001) 15, 1011-1021.
Introduction
Metazoan cells are able to initiate a series of events that causes the activation of intracellular proteases and ultimately results in the destruction of the cell. This is known as apoptosis or programmed cell death and is evolutionary ancient. 1 Apoptosis refers to both the initiation and execution of the events whereby a cell commits suicide and it is distinct from other forms of cell death. 2, 3 Two examples of non-apoptotic cell death are: (1) necrosis -cells die from external insults such as oxygen deprivation or exposure to cytotoxic chemical agents; 4, 5 (2) senescence -cells expire when they reach the end of their replicative lifetime. 6 Apoptosis is marked by an orderly series of hallmark biochemical and morphological events including cell shrinkage, mitochondrial breakdown and nuclear DNA fragmentation. 7 Eventually the dying cell degrades into apoptotic bodies that are subcellular membrane-bound vesicles that are ultimately removed by phagocytosis.
There are two reasons for a cell to undergo apoptosis. Firstly, the death of the cell may be required for normal development of a tissue or organ. The classic example is the resorption of the tail when a tadpole undergoes metamorphosis into a frog. 8 Apoptosis provides a means of cell elimination during development, tissue homeostasis and the removal of self-reactive immune cells. 4, 5, 9 In the lung, for example, apoptosis is involved in normal structural maturation during both fetal and postnatal development. 10, 11 Secondly, apoptosis is needed to destroy errant cells that pose a threat to the organism. For example, virus-infected cells are eliminated by the interaction with cytotoxic T lymphocytes that kill the virus-infected cells by inducing them to undergo apoptosis. 12, 13 Similarly, cells that have DNA damage undergo apoptosis. [14] [15] [16] [17] This eliminates cells that have accrued genetic mutations and may thereby become cancerous.
An important paradigm of the ontogeny of cancer came from the discovery of the roles of dormant proto-oncogenes that mutate into growth promoting oncogenes typified by such genes as src, ras and raf. [18] [19] [20] [21] However, on the other hand, there is another class of genes, known as tumor suppressors or anti-oncogenes, that suppress oncogenesis. 22, 23 For example, cell fusion experiments demonstrated that the malignant potential of cells can be abrogated by fusing them with normal cells. 24, 25 Some tumor suppressors are able to counteract the proliferative consequences of oncogenes through their ability to induce apoptosis. Our present understanding of cancer pivots on the understanding of these opposing influences and how this knowledge may be used for therapeutic intervention. Indeed, induction of apoptosis is the mode of action of many anti-tumor chemotherapeutic agents that are currently in use. [14] [15] [16] [17] 
How apoptosis transpires: caspase activation
Activation of the family of proteins known as caspases (cysteinyl, aspartate-specific proteases) constitutes the means of execution of apoptosis. [26] [27] [28] There are at least 14 caspases, the prototypical member (caspase 1 or ICE) being first recognized because of the sequence similarity between the nematode Caenorhabditis elegans developmental cell death gene CED-3 and mammalian interleukin-1␤-converting enzyme (ICE). 29 Caspases are synthesized as proenzymes that are activated by proteolysis at two or three sites to remove an Nterminal peptide and divide the proenzyme into a large and small subunit, which in some cases are separated by a linker domain. The mature caspase is a heterotetramer of two large and two small subunits. For example, procaspase 1 is a 45 kDa protein that is cleaved to give 20 kDa and 10 kDa subunits (p20 and p10) following removal of an 11 kDa Nterminal prodomain and a 2 kDa linker region of unknown function. 30, 31 All caspases are activated by cleavage at a specific aspartate residue. A model has been proposed in which caspases sequentially activate others, ie there is a cascade that begins with the activation of an 'initiator' caspase, eg caspase 8 (see below), which activates an 'amplifier' caspase, eg caspase 1, which in turn activates an 'effector' caspase, eg caspases 3 Leukemia and 7, that are responsible for the destruction by proteolysis of the cellular substrates responsible for apoptosis. 32 What are the protein substrates that are cleaved by caspases during the execution phase of apoptosis?
Poly(ADP-ribose) polymerase (PARP)
PARP is the best characterized substrate of caspases. Intact PARP (116 kDa) is cleaved into two fragments (89 kDa and 24 kDa) during apoptosis in many cell systems. 33, 34 Cleavage of PARP is a valuable indicator of apoptosis but its biological relevance is not known. Caspases 3 and 7 are primarily responsible for PARP cleavage. 26 
Caspase-activated deoxyribonuclease (CAD)
CAD is a cytoplasmic endonuclease whose activation is thought to be responsible for generating the oligonucleosomal DNA fragments that are the hallmark of apoptosis. 35 In nonapoptotic cells, CAD is inactive because of its association with an inhibitory protein (ICAD) which masks the nuclear localization sequence of CAD. Induction of apoptosis results in cleavage and inactivation of ICAD allowing CAD to translocate to the nucleus where it fragments the DNA. 36 
DNA-dependent protein kinase (DNA-PK)
DNA-PK is a DNA repair enzyme that is degraded during apoptosis by caspase 3. 36, 37 Degradation of DNA-PK will result in a decrease in the capacity of the cell to repair damage to nuclear DNA, thus facilitating the breakdown of DNA that is associated with apoptosis.
Lamins
Lamins are the major structural component proteins of the nuclear envelope. During apoptosis, lamins undergo proteolysis 38, 39 and this may be responsible for the observed morphological changes in the nucleus that are observed during the course of apoptosis. It is thought that caspase 6 is the major caspase responsible for lamin degradation. 40, 41 Fodrin, Gas2, actin Cleavage of the cytoskeletal proteins fodrin, 42 Gas2 43 and actin 44, 45 during apoptosis may induce cell shrinkage, membrane blebbing and alter cell signaling pathways. Consequent changes in the plasma membrane of the apoptotic cell are important for its recognition by phagocytic cells.
U1-70 kDa
U1 is a small ribonucleosomal particle that functions in the splicing of mRNA transcripts. One of its protein components U1-70 kDa is essential for its function and is cleaved during apoptosis. 37, 46 In this way, any cellular process that is dependent on new mRNA synthesis is blocked.
Translation initiation factors
When apoptosis is induced, the rate of cellular protein synthesis is rapidly diminished and this occurs at the level of translation initiation. Caspases cleave the initiation factors eIF4G, eIF4B, eIF2␣ and p35-eIF3. 47 Proteolytic cleavage of these factors may cause the inhibition of translation during apoptosis.
Cell signaling proteins
Certain cell signaling proteins are cleaved by caspases and this may contribute to apoptosis. For example, certain protein kinases are cleaved and rendered constitutively active and pro-apoptotic. These include protein kinase C-␦, 48 ,49 protein kinase C-, 50 MEKK-1 51 and hPAK65. 52 Conversely, protein kinases involved in anti-apoptotic pathways (eg Raf-1 and protein kinase B, also known as Akt) may be cleaved and inactivated by caspases. 53 Cleavage of APC and the tumor suppressor retinoblastoma protein, Rb, have been reported during apoptosis. 54, 55 Also the anti-apoptotic proteins Bcl-2 and Bcl-X L (see below) may be degraded during apoptosis.
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How apoptosis is initiated; mechanisms of induction of apoptosis
What makes a cell decide to kill itself? The survival of the cell hinges on the balance between positive and negative signals. Many cells require positive signals provided by external growth factors to survive (Figure 1 ). For example, nerve growth factor activates pro-survival signals in neuronal cells 58 and cytokines (interleukins) inhibit apoptosis of hematopoietic cells. 27, 59, 60 Negative signals include stress, oxidants, irradiation, and toxic chemicals, eg chemotherapeutic agents. Also discussed below are death activators, eg FasL and TNF.
There are two ways by which a cell is induced to undergo apoptosis: internal signals arising within the cell or external signals triggered by death activators that bind to receptors located at the cell surface. The pathways involved in both mechanisms are complex, redundant, interdependent and incompletely understood.
Apoptosis triggered from within: the apoptosome
The key to the initiation of apoptosis by internal signals is the mitochondrion. [61] [62] [63] The multi-protein complex that leads to the autoproteolytic activation of the upstream caspases is termed the apoptosome (Figure 1 ). Apoptosome formation is triggered by the release of cytochrome c from the mitochondrion. 64, 65 The released cytochrome c binds to Apaf-1, a cytoplasmic protein, which is induced to oligomerize and recruit and activate procaspase-9. 66 Active caspase-9 in turn activates the executioner caspase-3.
This mitochondrial pathway is controlled by the Bcl-2 family of proteins.
The Bcl-2 family of proteins: the finger on the button
The Bcl-2 family of cytoplasmic proteins are key regulators of the internal pathway of apoptosis induction. [67] [68] [69] The prototype of this family, Bcl-2, is a proto-oncogene that is activated Effects of cytokines on the prevention of apoptosis. This figure illustrates the effects of cytokines on the activation of the PI3K/Akt, Ras/Raf/MEK/ERK and Jak/STAT pathways. Kinases and transcription factors are indicated in green as is the cytokine receptor. Pro-apoptotic molecules such as activation of the caspase cascade, decrease in the mitochondrial membrane potential and the FKHR transcription factor are indicated in black.
by translocation in human follicular lymphoma. 70 Rather than exerting an effect on cellular proliferation, activated Bcl-2 was found to exert its effect by promoting cell survival. Thus Bcl-2 permits cytokine-dependent hematopoietic cells to survive in a quiescent state in the absence of cytokine 71 and co-operates with the Raf-MAPK pathway in transforming hematopoietic cells. [72] [73] [74] [75] An anti-apoptotic cell death gene in C. elegans, CED-9, proved to be a structural and functional homologue of Bcl-2 demonstrating the remarkable evolutionary conservation of the apoptotic machinery. 76, 77 There are at least 15 members of the Bcl-2 protein family that share homology in at least one of three conserved domains (BH1-BH4) and these may either promote survival, eg Bcl-2, Bcl-X L or promote apoptosis, eg Bax, Bak. [67] [68] [69] A second type of pro-apoptotic subfamily known as the BH3-only proteins possess only the central short BH3 domain eg Bid, Bad, Blk, Noxa. The Bcl-2 family of proteins are able to register a variety of stimuli both positive and negative and integrate them to determine whether the mitochondrial apoptotic pathway is turned on or off. Pro-and anti-apoptotic family members are able to form heterodimers with each other and this has led to the idea that their relative abundance may act as a rheostat controlling the mitochondrial initiation pathway. 78 Interaction of Bax with Bid causes Bax to oligomerize and Leukemia insert into the outer membrane of the mitochondrion 79 triggering the sudden and complete release into the cytoplasm of cytochrome c and other proteins from the intermembrane compartment of all of the cellular mitochondria. 28, 80 As discussed above, this causes procaspases' activation. Bcl-2 protects against cell death by blocking the release of proteins from the intermembrane space of the mitochondrion. However, once this release has occurred, the mitochondrial apoptotic initiation process is beyond the point of no return and can no longer be prevented by Bcl-2 family members. 81 The importance of the Bcl-2 family of proteins is underscored by reports of their dysregulation in many hematological malignancies that can contribute to the resistance of such malignancies to pro-apoptotic chemotherapeutic drugs.
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Apoptosis due to the cell receiving an abnormal proliferative signal
Oncogenes encode mutated versions of the signaling proteins that control normal cell proliferation. The effects of oncogenes such as Ras on proliferation and tumorigenesis have been well-documented in immortal cell lines. [91] [92] [93] However, there is evidence that mechanisms exist in many other types of cells whereby abnormal Ras signaling actually induces apoptosis.
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This may reflect a defense mechanism against pathological changes in this crucial signaling nexus that eliminates potential neoplastic cells. Antiproliferative responses of oncogenic Ras were observed in non-transformed fibroblasts, primary rat Schwann cells, rat pheochromocytoma PC12 cells, NIH-3T3-L1 fibroblast cells, and primary fibroblasts of human and murine origins. [94] [95] [96] [97] [98] [99] It is believed that the cell proliferation arrest induced by oncogenic Ras was not an immediate outcome of Ras signaling, but a late cellular response due to abnormal Ras activity. In the fibroblasts that were transfected with oncogenic Ras, induction of cell cycle inhibitors, p16
Ink4a , p21 Cip1 and p53 as well as decreases in the levels of cyclin A and Cdk2 kinase activity and hyperphosphorylated pRb, were observed. In p53 −/− and p16 −/− mutant fibroblasts, proliferation was observed in the presence of oncogenic Ras. Thus, p53 and p16
Ink4a tumor suppressor genes are essential for the cell cycle arrest mediated by Ras.
Similarly, overexpression of an activated form of the Raf oncoprotein has also been associated with cell cycle arrest in some cell lines, including rat Schwann cells, mouse PC12 cells, human promyelocytic leukemia HL-60 cells, and small cell lung cancer (SCLC) cell lines. [100] [101] [102] [103] In contrast, T cell differentiation is accelerated in transgenic mice expressing activated Raf in the thymus. 104 It is not clear why over-expression of the Raf gene can lead to such conflicting results, but recent reports have suggested that it is the amount or activity of the Raf oncoprotein that leads to the opposite outcomes. 73, 74 Depletion of Raf-1 was shown to abrogate p21
Cip1 induction after taxol treatment in a human prostate cancer cell line. 100 Furthermore, recent studies involving conditionally active ⌬Raf:ER proteins have implicated the Raf family of kinases in cell cycle control. 105, 106 Raf-1 was determined to be sufficient for p21
Cip1 induction as long as the MEK/ERK pathway was left intact. 101 Further study of Raf-mediated p21 Cip1 induction has led to a model that integrates proliferative signals with cell cycle arrest. The effect of Raf activation seems to be determined either by the level or duration of Raf activity in the cell. Upon stimulation, Raf delivers a proliferative signal that results in immediate-early gene activation and induction of the cyclins. However, prolonged signaling through the MEK/ERK proteins results in induction of p21
Cip1 and cell cycle arrest. This dual activity of Raf might serve as a means of feedback inhibition and could maintain checks and balances on the generation of proliferative signals. The three different Raf proteins have varying levels of kinase activity. 73, 74 Thus, one would expect differences in the biological effects of A-Raf, B-Raf and Raf-1. This is supported by the fact that A-Raf, a weaker kinase than either B-Raf or Raf-1, is a poor inducer of p21
Cip1 expression while B-Raf and Raf-1 can readily induce p21
Cip1 and cell cycle arrest in NIH-3T3 fibroblasts. 74 In NIH-3T3 cells transfected with different Raf genes, Raf molecules are able to upregulate the expression of cyclin D1, cyclin E, Cdk2 and Cdk4 and downregulate the expression of Cdk inhibitor p27 Kip1 . 106 These changes induce cells to pass through G1 phase and enter S phase. However, in B-Raf and Raf-1 transfected cells, there was also a significant induction of p21
Cip1
. Study of Raf-mediated cell cycle arrest should provide multiple targets for therapeutic intervention in malignancies involving a deregulated cell cycle.
Apoptosis triggered from without: death activators and their receptors
The second way in which the apoptotic program can be initiated is by way of the action of extracellular messengers, termed death ligands. These bind to cell surface receptors, termed death receptors, that activate intracellular signaling events that begin an apoptotic cascade. [107] [108] [109] That certain cells can be 'instructed' to undergo apoptosis is important especially in the immune system. 110 Death receptors belong to the tumor necrosis factor (TNF) receptor superfamily that is characterized by a cysteine-rich extracellular ligand-binding domain. 111 Death receptors contain a consensus module known as the death domain that is found in the intracellular portion of the molecule and is involved in transducing the apoptotic signal. 112 116,117 Procaspase 8 undergoes self-cleavage and activation following its oligomerization at the Fas-associated protein complex. This in turn activates effector caspases committing the cell to apoptosis as described above.
The TNF receptor also signals to activate caspase 8 through death adapter proteins, but TNF alone rarely induces apoptosis perhaps due to the intervention of anti-apoptotic pathways such as NF-B, JNK and phosphatidylinositol 3-kinase (PI3K) 107, 117, 118 and these are discussed later. Other members of the TNF/FasL family of death ligands have been identified by screening DNA sequence databases. TRAIL (TNF-related apoptosis inducing ligand, also known as Apollo) is closely related to FasL 119, 120 and, like FasL, potently induces apoptosis in tumor cells 78 as does another family member, TWEAK. 107 Other members of the superfamily of receptors for these ligands (death receptors) have been found that are pro-apoptotic eg DR3, DR4, DR5 and DR6. Interestingly, there are death receptors homologs that do not contain effective cytoplasmic signaling domains, and thus complete for death ligand, and are known as decoy receptors, eg DcR1, DcR2, DcR3 and osteoprotegrin.
108,109
Protection from apoptosis: the other side of the coin
The life or death decision-making process responsible for apoptosis hangs in the balance of positive and negative influences. We have described the molecular events whereby apoptosis is initiated and executed. Throughout this process, from receipt of the initial apoptotic stimulus until activation of the terminal executioner caspase, anti-apoptotic counterbalances exist that may intervene and save the life of the cell. An inappropriate equilibrium at some point during the program of cell death, resulting from either abrogation of a proapoptotic process or improper induction of an anti-apoptotic occurrence, can be a major factor in the etiology of neoplasia.
The 'inhibitors of apoptosis' (IAPs): the brakes on the machine
IAPs are a group of cellular proteins that act to directly inhibit specific caspases and thereby inhibit apoptosis. 121, 122 IAPs were first discovered as viral proteins encoded by insect baculoviruses that enhance virus replication. 123, 124 Apoptosis of cells in response to viruses is a host defense mechanism against viral infections and many viruses have evolved strategies to circumvent this. 125 Thus the genomes of many viruses encode proteins that block apoptosis and baculovirus IAP is such a protein. Within this protein is a conserved functional domain known as the baculovirus IAP repeat (BIR) found in all IAPs that has conserved cysteine and histidine residues that facilitate co-ordination of a zinc ion in a fashion similar to the classical zinc finger motif of DNA-binding proteins. 126 At the present time, six mammalian IAPs have been identified. These are: inhibitor of apoptosis-1 (c-IAP1), inhibitor of apoptosis-2 (c-IAP2), neuronal apoptosis inhibitory protein (NAIP), survivin, X-linked inhibitor of apoptosis (XIAP), and BIR repeat-containing ubiquitin-conjugating enzyme (BRUCE). These endogenous inhibitors of apoptosis form an essential part of the apoptotic machinery and serve to protect cells from indiscriminate induction of death. However, they are also implicated in the progression of malignancies. 127 Overexpression of exogenous IAPs in cells protects them from the induction of apoptosis. 128, 129 Survivin is expressed in many cancers and transformed cell lines 127 and may contribute to their resistance to apoptosis. 129 In normal cells, survivin is expressed in the G2/M phase of the cell cycle and associates with the microtubules of the mitotic spindle in a specific and saturable manner. 130 If this interaction is disrupted, survivin loses its anti-apoptotic activity indicating that survivin may counteract default induction of apoptosis at a G2/M phase mitotic signal checkpoint. Overexpression of survivin in malignant cells may thus allow them to progress aberrantly through mitosis. 130 Induction of c-IAP1 and c-IAP2 expression has found to be a consequence of the NF-B anti-apoptotic pathway (see below). For example, TNF activates NF-B which induces the transcription of c-IAP1 and c-IAP2 and thereby suppresses caspase-8 activation. 131 Besides the defining BIR domain that is found in all IAPs and is essential for their function, some IAPs (XIAP, c-IAP1 and c-IAP2) also have a domain known as a RING finger. Recently this domain has been implicated in the process of ubiquitin conjugation. 132 Ubiquitin conjugation to a protein is part of the process whereby it is targeted for proteolysis by the proteasome. This process is important in cell cycle regulation and signal transduction and involves distinct classes of enzymes denoted as E1, E2 and E3. The RING finger domain is thought to be involved in E3 ubiquitin ligase activity. 132 c-IAP1 and XIAP are selectively lost when thymocytes are induced to undergo apoptosis by etoposide or glucocorticoids and this loss is proteasome-dependent. 133 IAPs are able to auto-ubiquitinate and this activity requires the RING domain. Overexpressed IAPs are spontaneously ubiquitinated and degraded but not a RING domain mutant. Thus lack of the RING domain makes IAPs more effective at preventing apoptosis. 133 Auto-ubiquitination of IAPs may be an important part of the apoptotic process.
Finally, a further level of complexity has recently been revealed by the discovery of proteins that bind to and inhibit IAPs. Du et al 134 reported a novel protein, Smac, that is released from mitochondria when cells undergo apoptosis.
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Verhagen et al 135 identified a protein, DIABLO (direct IAP binding protein with low pI) that coimmunoprecipitates with XIAP and is released into the cytosol during apoptosis counteracting the effect of XIAP.
Help from the outside: how extracellular cytokines protect cells from apoptosis
As discussed above, the survival of a cell depends on a balance between positive and negative signals. Positive signals provided by external growth factors (Figure 1 ) promote cell survival, eg nerve growth factor activates survival signaling in neuronal cells 58 and cytokines inhibit apoptosis of hematopoietic cells. 27, 59, 60 The phosphatidylinositol 3-kinase pathway
The anti-apoptotic signal from receptors for extracellular growth factors and cytokines is delivered through the enzyme phosphatidylinositol 3-kinase (PI3K). 58, [136] [137] [138] PI3K is the prototypical member of a family of enzymes that phosphorylate phosphatidylinositol on the 3Ј position of the inositol ring (reviewed in Ref. 139 ). In addition to its protective role against apoptosis, this enzyme plays a central role in a diverse range of cellular responses including cell growth and differentiation, metabolic regulation, membrane trafficking and control of the cytoskeleton. 139 The first evidence for PI3K involvement in signaling from cell surface tyrosine kinase receptors was the observation that PI3K activity and an 85 kDa phosphoprotein were recruited into anti-phosphotyrosine immunoprecipitates after stimulation of cells with platelet-derived growth factor PDGF. 140, 141 Signaling pathways initiated by receptor tyrosine kinases depend on the recruitment of signaling proteins that bind to phosphotyrosine residues resulting from activation of the receptor tyrosine kinase activity (Figure 1) . These phosphotyrosines may either be present on the receptor protein itself (ie autophosphorylation sites) or on a transphosphorylated receptor-associated substrate protein (eg IRS-1). 142 Protein modules known as Src homology-2 (SH2) domains 143 mediate binding of signaling proteins to phosphotyrosine residues. PI3K was one of the first signaling proteins found to operate in this way. It has two subunits p85 and p110 that serve regulatory and catalytic functions, respectively. The regulatory subunit has an SH2 domain and binds to the phosphorylated tyrosine residues. Examples include the PDGF receptor that has undergone tyrosine autophosphorylation as a result of ligand binding 132 and IRS-1 that has been phosphorylated by the insulin receptor. 142 The binding of p85 to such upstream phosphoproteins activates the p110 catalytic subunit that transfers phosphate from ATP to phosphatidylinositides (Figure 2 ). Phosphatidylinositides that are phosphorylated on the 3Ј position are second messengers that activate downstream signaling molecules such as the serine/threonine protein kinase B (PKB, also known as Akt). 144, 145 Like other molecules that bind 3Ј-phosphorylated phosphoinositides, PKB/Akt contains a pleckstrin homology (PH) domain that serves to target it to the membrane. Once targeted to the membrane (Figure 2 ), PKB/Akt is phosphorylated by two enzymes, phosphatidylinositol 3,4,5-triphosphate-dependent kinase-1 (PDK1, which is itself has a PH domain and is activated by 3Ј-phosphorylated phosphoinositides) and PDK2 leading to full PDK acti- vation. 146 Activation of PKB/Akt is prevented by pharmacological inhibitors of PI3K, by dominant negative mutants of PI3K or by deletion of the tyrosine residues from tyrosine kinase receptors that mediate binding of the PI3K p85 subunit. On the other hand, introduction of constitutively activated mutants of the p110 catalytic subunit into cells activates PKB/Akt. Thus PKB/Akt is clearly downstream from PI3K. 144, 145 There are three known mammalian isoforms of PKB/Akt -␣, ␤ and ␥. Identification of targets that are phosphorylated by PKB/Akt is an area of intensive research. Biological consequences of PKB/Akt action include alteration of cellular carbohydrate metabolism, stimulation of protein synthesis, and suppression of apoptosis.
What targets of PKB/Akt are important in delivering the apoptotic signal? PKB/Akt phosphorylates the pro-apoptotic protein Bad (discussed above). 147, 148 Phosphorylation of the pro-apoptotic protein Bad by PKB/Akt results in its inactivation and hence should favor cell survival (Figure 2) . However, it is unlikely that Bad phosphorylation represents the major mechanism by which PKB/Akt acts as an inhibitor apoptosis in most cell types because Bad is not ubiquitously expressed. 149 Other protein targets of PKB/Akt may be responsible for surfactant-associated protein-A (SP-A) protection from apoptosis, eg caspase-9. 150 The PKB/Akt phosphorylation site in caspase-9 is present in the human but is not conserved in rodents. 151 Thus, caspase-9 phosphorylation by PKB/Akt may be involved in the protection from apoptosis of human cells but not in mouse or rat cells. However, there is evidence for the existence of an additional, evolutionarily conserved mechanism by which PKB/Akt can suppress activation of caspases (discussed in Ref. 152) . A third type of protein that are targets for PKB/Akt are the forkhead transcription factors such as FKHRL1 that are potent at inducing apoptosis, an event that can be inhibited by phosphorylation by PKB/Akt. 153, 154 PKB/Akt phosphorylates and inactivates glycogen synthase kinase-3 (GSK-3) and thereby mediates the activation of glycogen synthesis by insulin. 144, 145 There is also evidence that GSK-3 delivers an anti-apoptotic signal. Thus transfection of a catalytically active GSK-3 into fibroblasts induced apoptosis while a dominant negative form of GSK-3 prevented apoptosis. 155 Although the details of the downstream signaling pathways remain to be elaborated, clearly the PI3K-PKB/Akt pathway is a powerful protector of cells against apoptosis. Dysregulation of this pathway can contribute to oncogenesis. For example, the PKB/Akt is the cellular homologue of the v-akt oncogene of the AKT8 transforming retrovirus. 144, 145 In addition, mutation in a lipid phosphatase, PTEN (also known as MMAC1 and TEP1), that removes the phosphate from the 3Ј position of the inositol ring of 3Ј-phosphoinositides can pathologically boost the cellular levels of 3Ј-phosphoinositide second messengers activating PKB/Akt and promoting oncogenesis. 156, 157 PTEN is a dual specific lipid and protein phosphatase with homology to the cytoskeletal protein tensin that acts to restrain the PI3K-PKB/Akt pathway and is an important tumor suppressor gene product that is mutated in a variety of tumors. 156, 157 PTEN is also mutated in the germline of a variety of human autosomal cancer predisposition syndromes including Cowden disease, Bannayan-Zonana syndrome and Lhermitte-Duclos disease that are characterized by developmental defects and tumor susceptibility. 158 Mutations in PTEN have been found in a significant percentage of several types of leukemia including acute myeloid leukemia, 159 lymphoblastic leukemia/lymphoma, large B cell lymphoma, Burkitt's lymphoma, 160 ,161 B cell non-Hodgkin's lymphoma, 161, 162 and primary cutaneous T cell lymphoma. 163 These observations indicate that restoration of PTEN function is an attractive target for gene therapy of certain subclasses of neoplasm.
Role of the Rel/NF-B transcription factors in the control of apoptosis
The Rel/NF-B family of transcription factors are comprised of several related proteins including c-rel, RelA, RelB, p50/p105, and p52/p100 that are induced in response to many signals and are involved in cell growth, differentiation, neoplasia, inflammation and the control of apoptosis. 164, 165 Rel/NF-B proteins form homo-or hetero-dimers and control the expression of many genes by binding to DNA regulatory elements known as B sites. The most common heterodimer found in most cell types is p50-RelA (NF-B) which is retained in an inactive form in the cytoplasm through association with an inhibitor protein, IB. Several forms of IB exist -IB␣, -␤, -⑀, -␥, p105, p100 and Bcl-3. 166 In response to a variety of stimuli, IB becomes phosphorylated leading to its polyubiquitination and consequent degradation by the proteosome allowing the release of NF-B that is then translocated to the nucleus where it modulates gene expression. The kinase that phosphorylates IB is a high molecular weight protein complex, IkappaB-kinase (IKK), containing two subunits IKK␣ and IKK␤ together with a modulator known as NF-B essential modulator (NEMO). 167 In certain cell types, eg B cells, there may be a high level of basal or constitutive NF-B activation. 165 Constitutive NF-B activation and nuclear B site binding and transactivation activity may also be found in many tumor cells. 168 A role for NF-B transcription factors in suppressing apoptosis was first indicated by study of the oncogene v-rel from the avian retrovirus reticuloendotheliosis virus stain T 169 which causes leukemia in chickens and whose cellular homologue is c-rel. 170 Vrel renders chicken B cells resistant to radiation-induced apoptosis 171 and chicken spleen cells transformed by temperature-sensitive v-rel proteins undergo apoptosis when cells are shifted to the non-permissive temperature. 172 NF-B was first described as a nuclear protein promoting immunoglobulin light chain transcription in B cells 173 and has subsequently been shown to mediate survival signals that protect against apoptosis in most cells (although it may be proapoptotic under some circumstances). [174] [175] [176] As discussed above, the pro-inflammatory tumor necrosis factor (TNF) binds to a death receptor leading to the activation of caspase 8. However, TNF alone rarely induces apoptosis perhaps due to the intervention of anti-apoptotic pathways. 107, 111, 118 The proapoptotic signal from the TNF receptor (that leads to caspase activation) is transduced through FADD as described above, while the anti-apoptotic signal (that leads to the activation of NF-B) is transduced through an adapter molecule named TNF-receptor-associated factor 2 (TRAF2). 177 Activation of NF-B by TNF requires the successive action of NF-B-inducing kinase (NIK) and IKK. 164 Furthermore, the PI3K-PKB/Akt pathway described above also appears to be involved in the activation of IKK as well as NIK. 178 Thus wortmannin (a PI3K inhibitor), a dominant negative PI3K or a kinase-dead PKB/Akt inhibit TNF-mediated NF-B activation while constitutively active PKB/Akt activates NF-B, an effect that is blocked by dominant negative NIK. 178 Thus PKB/Akt appears to function in parallel with NIK to activate IKK. Similarly, the PI3K-PKB/Akt pathway ( Figure 2) is involved in the activation of NF-B by PDGF, 179 insulin, 180 IGF-1 181 and NGF. 182 Activation of NF-B has a role in the anti-apoptotic signaling of these cytokines.
The mechanism whereby NF-B promotes cell survival is due, at least in part, to the induction of the transcription of a number of anti-apoptotic genes and these have recently been reviewed. 165 Experimentally, the role of a gene in suppressing apoptosis can be demonstrated by showing that: (1) it is upregulated by activation of NF-B; (2) inhibiting the gene product abrogates apoptotic protection; (3) ectopic expression of the gene is anti-apoptotic. Such genes include members of the Leukemia Bcl-2 family (Al/Bfl1, Bcl-X L and Nrl3), death receptor signal transduction proteins (TRAF1 and TRAF2), inhibitors of apoptosis (c-IAP1, c-IAP2 and X-IAP), transcription factors (c-myc and p53). 165 Inhibition of NF-B nuclear translocation enhances apoptotic cell killing by TNF, ionizing radiation, overexpression of oncoproteins or the cancer chemotherapeutic agent daunorubicin. Thus, activation of NF-B is a mechanism of cellular resistance to killing and this may offer insights for potential improvement of the efficacy of cancer therapies. 166, 183, 184 
Conclusions
Apoptosis is a very tightly regulated cellular program with many levels of checks and balances. The multitude of players involved in this process is indicated by the profusion of proteins described in this review. In fact, we have only scratched the surface. Apoptosis is intimately connected to the machinery of the eukaryotic cell cycle with its DNA-damage-induced checkpoints and connection to DNA repair. Several tumor suppressor genes, eg ATM, NBS1, BRCA1, BRCA2, Rb and the p53 gene family, are involved in these processes and cancer is often associated with the mutation and compromise of the function of one or more of these genes. [185] [186] [187] [188] [189] [190] Addressing this big picture is beyond the scope of this review. Rather, we have concentrated on the mechanisms of execution of programmed cell death and how their suppression is involved in the etiology of malignancy. Understanding the complexities of the interplay of the opposing signaling events that promote and suppress apoptosis in normal and neoplastic cells will be an important guide in providing a framework for the design of new therapeutic interventions.
